A ptamers are single-stranded DNA or RNA oligonucleotides that can bind a wide range of biomedically relevant molecules, such as proteins, drugs, small molecules, and biological cells, with high affinity and specificity. Because of these properties, aptamers can serve as either biological drugs or drug carriers to treat various diseases. Although they have often been described as analogues of antibodies, 1 aptamers exhibit significant advantages relative to protein therapeutics in terms of small molecular size, reproducible synthesis, and low immunity; further, they can be easily modified by chemical synthesis, making them more adaptable for different biomedical applications. Moreover, advances in chemical synthesis methods have enabled the generation of large populations of degenerate oligodeoxynucleotides, enabling the in vitro selection of aptamers using systematic evolution of ligands by exponential enrichment (SELEX), a combinatorial chemistry technique in molecular biology for producing oligonucleotides of either single-stranded DNA (ssDNA) or RNA that specifically bind to a target ligand or ligands. 2, 3 In view of these advantages, aptamers show considerable potential in therapeutic applications. However, aptamers confront some application challenges. First, RNA and DNA molecules are susceptible to nucleasemediated degradation, thus limiting their use in some therapeutic applications. 4 Second, as chemicals, aptamers cannot readily cross biological barriers, such as cell membranes, to perform target-specific recognition inside cells. 5 However, chemical modifications can generally be incorporated into the nucleotide sugars or internucleotide phosphodiester linkages to circumvent these problems. As shown in Table 1 , aptamers can be easily assembled on the surface of carbon nanotubes, quantum dots, and metallic or silica nanoparticles by noncovalent physical adsorption or through covalent interactions.
6À10
Such modifications of nucleotides can both stabilize aptamers against nuclease-mediated degradation and increase their solubility and binding affinity. 11 Encapsulation-based aptamer protection and delivery using silica, polymers, or gels is another way to prevent enzymatic degradation while being delivered across cell membranes. However, limitations, such as cell toxicity, low biocompatibility, and biophysical and chemical instability, have prevented the full realization of aptamer delivery in vivo. The ideal delivery vehicle should protect aptamers from the physiological environment and minimize metabolism and degradation during transit. It should also be biocompatible, biodegradable, stable, and able to be engineered such that aptamer molecules are concentrated at the desired site of action to increase efficacy while, at the same time, decreasing unwanted side effects. 
PERSPECTIVE
Natural biomaterials, including lipids, proteins, and oligosaccharides, have been used to construct delivery platforms by encapsulating their cargos into diverse nanocontainers, 12 such as cages, microspheres, nanoparticles, hydrogels, minirods, and minipellets. This type of development has especially focused on protein-based delivery platforms due to the biocompatibility, biodegradability, and low toxicity of some natural proteins. A variety of such proteins have been used and characterized, including viral capsids, 13, 14 
OUTLOOK AND CHALLENGES
Lau et al.'s strategy suggests a general platform for the production of VLPs to encapsulate aptamers. Favorable biocompatibility and biodegradability and uniform size are the advantages of VLPs for the delivery of modified aptamers to their target release sites. It has been shown that VLP encapsulation protects aptamers and their small-molecule ligands from degradation by erosion and proteolysis. Furthermore, since the flow rate of smallmolecule ligands is driven by the concentration difference between the interior and exterior of the VLPs, the release rate of molecules can also be regulated by VLP channel sizes to avoid the use of high doses of drugs. Virus-like particles are a major breakthrough for aptamer delivery in protein-based templates. Specifically, VLPs have improved the pharmacokinetics and biodistribution of aptamer delivery by improving the drug release mode.
Nonetheless, some challenges still confront VLP-based aptamer delivery systems. First, the properties and applications of VLPs are still in the development stage for aptamer delivery and therapeutic purposes. Most viruses developed for bionanotechnology applications have not yet been evaluated; hence, the use PERSPECTIVE of these viruses may be limited in aptamer delivery as a result of potential cytotoxicity. For example, human adenoviruses, which are typically used for gene delivery purposes, once resulted in severe hepatotoxicity in murine models. 21 Such toxic effects have also been observed in non-human primates. 22 Second, for clinical aptamer delivery, the biodegradability and immune response of VLPs still need to be evaluated, especially if modifications are decorated on the exterior surface of VLPs, such as folic acid and antigenic peptides. Third, fundamental questions about pharmacokinetic profiles and therapeutic efficacy of VLP-based aptamer Figure 1 . Schematic of the structure of virus-like particle encapsidating aptamers and small-molecule ligands of aptamers. The capsid shell provides channels for small-molecule ligands, as well as sufficient space for encapsulated aptamers to maintain their secondary and tertiary structures.
PERSPECTIVE delivery systems remain to be answered. Finally, future developments for VLP-based aptamer delivery should also focus on enhanced site-specific drug delivery by using newly developed receptor-targeting ligands, improving sustained drug release rates with enhanced permeability and retention time, minimizing damage to normal cells by directing drug molecules for site-avoidance delivery, and developing multiple drugs for sequential release.
